The use of COVID vaccines for babies and children is about to be decided based on?
Eighteen sitting Congressional members wrote a strong letter to the FDA demanding answers prior to the decision by regulators to approve COVID-19 vaccines for babies and young children aged 6 months to 4 years old. The FDA VRBPAC advisory panel is scheduled to meet on June 15 to discuss authorization and this letter addresses the fact that there are questions and facts that the FDA must consider prior to EUA authorization.
The letter clearly states that COVID-19 poses little risk to babies and young children, that the vaccines have little effectiveness against new variants, that there are many unanswered questions about the safety of the vaccines and that there is evidence of significant adverse events. Therefore, the lawmakers queried the FDA panel as to why these vaccines are necessary for this age cohort.
“The broad approach of the CDC and FDA to date has been a one-size fits all policy—get the vaccine regardless of age, risk factors, the underlying health of the individual, or previous infection,” the members wrote to FDA Commissioner Robert Califf and members of the advisory panel in a June 7 letter obtained by The Epoch Times. “Yet, to date there remain many unanswered questions about these EUA-approved COVID-19 vaccines and only a small percentage of the safety data about these vaccines that are in the possession of the FDA and the manufacturers has been released for review.”